Results 221 to 230 of about 106,101 (300)

Management of Primary Refractory Diffuse Large B‐Cell Lymphoma in Patients Unsuitable for CAR T‐Cell Therapy

open access: yesEuropean Journal of Haematology, Volume 116, Issue 6, Page 771-784, June 2026.
ABSTRACT Primary refractory Diffuse Large B‐Cell Lymphoma is associated with poor outcomes and limited responsiveness to conventional salvage therapies. Although CAR T‐cell therapy represents the standard of care in this setting, a substantial proportion of patients cannot receive it despite meeting disease‐related criteria. In this review, “unsuitable”
Santino Caserta   +12 more
wiley   +1 more source

Changes in the 6th edition of the World Health Organization classification of tumours of the digestive system

open access: yesHistopathology, Volume 88, Issue 7, Page 1295-1314, June 2026.
Changes and new entities in the 6th edition WCT of the digestive system, including structural, molecular, and diagnostic updates to standardize terminology and improve clinical relevance. Epithelial tumours are organized by site; neuroendocrine, mesenchymal and haematolymphoid tumours have dedicated chapters, with refined grading, redefined ...
Mark J Arends   +48 more
wiley   +1 more source

Manufacturing and clinical applications of non‐CAR‐T immune effector cells

open access: yes
Transfusion, EarlyView.
Thane Kubik   +2 more
wiley   +1 more source

Hematopathology Practice in the Digital Era: What has Changed?

open access: yesInternational Journal of Laboratory Hematology, Volume 48, Issue 3, Page 503-511, June 2026.
ABSTRACT Hematopathology workflows are complex, since they include numerous data points necessary for guiding further testing, diagnosis, and patient management. The workflows start with complete blood cell counts, with subsequent morphologic evaluation of peripheral blood (PB) and bone marrow (BM).
Olga Pozdnyakova
wiley   +1 more source

Targeting TNBC: core–shell polycationic polyurea dendrimers with inherent anticancer activity

open access: yesFEBS Open Bio, Volume 16, Issue 5, Page 944-965, May 2026.
Core–shell polycationic PURE dendrimers were tested in TNBC‐derived tumor models. Both formulations selectively targeted TNBC and effectively reduced tumor volume. PUREG4‐OEI48 suppressed tumor growth without detectable toxicity, whereas PUREG4‐OCEI24, despite showing efficacy, induced hepatic toxicity.
Adriana Cruz   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy